
Catalog No.: 100970
Net Contents: 1 x 15.0 mg AggRecetin (Ristocetin)
1 x 2.0 mL Diluent
AGGRECETIN® 10 - 15mg Ristocetin A Sulfate
AggRecetin® (Ristocetin) Reagent: A Trusted Standard for Ristocetin-Induced Platelet Aggregation (RIPA) Testing
AggRecetin (Ristocetin) Reagent is intended for use in performing routine Ristocetin-Induced Platelet Aggregation (RIPA) testing on Platelet-Rich Plasma (PRP) samples to assess platelet function.
-
Optimized for RIPA Testing: Delivers reliable platelet aggregation results at both low and high Ristocetin concentrations.
-
Low-Dose RIPA Sensitivity: Facilitates detection of hyper-responsiveness in type 2B vWD and PT-vWD patients.
-
High-Dose RIPA Confirmation: Verifies normal platelet-vWF interaction or rules out qualitative defects in vWF.
-
Supports Targeted Guidelines: Aligns with international guidelines for vWD classification and platelet function evaluation.
-
Enables GPIb-vWF Binding Assessment: Reveals abnormalities in platelet receptor binding activity central to vWD pathology.
AggRecetin® (Ristocetin) Reagent offers the same trusted, high-purity formulation in a size that fits your lab’s specific needs. Whether you’re running routine RIPA assays or conducting more focused evaluations, this conveniently packaged option ensures flexibility without compromising performance. Each lot contains over 90% pure Ristocetin, delivering the consistent quality required for sensitive platelet aggregation testing.
This formulation is expertly optimized for Ristocetin-Induced Platelet Aggregation (RIPA) testing, supporting both low-dose and high-dose protocols. Low-dose RIPA is essential for detecting heightened platelet responsiveness, a hallmark feature of type 2B von Willebrand Disease (vWD) and platelet-type vWD. High-dose RIPA offers confirmatory insights into the integrity of the platelet-vWF binding pathway, making this reagent critical in distinguishing between normal function and qualitative defects in vWF.
AggRecetin integrates seamlessly into guidelines recommended by major hematology and coagulation societies. Its performance supports comprehensive vWD subtype classification while maintaining compatibility with light transmission aggregometry (LTA) platforms. This allows clinicians and laboratorians to align testing strategies with evidence-based guidelines and make timely, informed decisions.
With AggRecetin, your lab gains a powerful analytical tool for investigating platelet receptor function and vWF interaction. Its ability to uncover abnormalities in the GPIb-vWF binding mechanism strengthens clarity in complex bleeding disorders. In every vial, you’ll find precision, reliability, and the support you need to uphold the highest standards in hemostasis testing.
Please delve into the literature provided on this page, including the AggRecetin Reagent Product Data Sheet, Routine Agonist Expected Results Chart, and the AggRecetin Instruction for Use (IFU), along with the AggRecetin Safety Data Sheet (SDS) — available in six languages. Furthermore, for our European and United Kingdom customers and distributors, examine the AggRecetin EU Declaration of Conformity and the AggRecetin UK Declaration of Conformity to ensure compliance and understanding tailored specifically for these regions. This information is essential for a thorough understanding of the product details and specifications.